ADOCIA has announced that it will hold its annual meeting in Paris on June 28, 2022.

Lyon, France – (BUSINESS WIRE) – Regulatory News:

Adocia (Paris: ADOC) (Euronext Paris: FR0011184241 – ADOC), a clinical biopharmaceutical company specializing in the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, is the General Assembly. Announced to be held (“AGM”) June 28, 2022 at 10 am, Hôtel de Talleyrand, Company Jones Day, 2 rue Saint Florentin, 75001 Paris Office.

The notice of the meeting, which acts as a call, was published today at Bulletin des Annonces Légales Obligatoires (“BALO”) and includes the agenda, the text of the resolution, and the procedure for attending and voting in this meeting.

All documents related to the meeting are available to shareholders under the conditions stipulated by the regulations in force and are available on our website (https://www.adocia.com/en/investors/shareholder-information/). ) Can be obtained.

Explanation about AGM

Only shareholders who have registered their shares by midnight Paris time, two business days before the AGM set date, can physically participate in AGM. For shareholders holding bearer shares, the approved intermediary must provide a “Certificate of Participation”. This certificate must be attached to the voting rights exercise form of shareholders who wish to exercise their voting rights or exercise their voting rights by mail. The certificate of participation may replace the admission card of shareholders wishing to attend the Ordinary General Meeting of Shareholders.

Written questions from shareholders must be received by registered mail, registration office, or email at the following address at least 4 business days prior to the Joint General Assembly: [email protected] Your account registration certificate must be attached to process your question and must be submitted at least 4 business days prior to the General Assembly date.

About Adoshia

Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions primarily in the areas of metabolic disorders such as diabetes and obesity. The company has a large portfolio of candidate drugs from three proprietary technology platforms.

1) Bio chaperone®, A technique for developing new generations of insulin and combinations that associate insulin with other hormone families. 2) AdOral®Oral peptide delivery technology; 3) TeenShell®An immunoprotective biomaterial for cell transplantation, with initial application to pancreatic cells for patients suffering from so-called “unstable” diabetes.

Adocia has more than 25 patent families and is ranked 4th.th And 7th In the SME INPI ranking on the number of patents filed in 2019 and 2020.

Based in Lyon, the company has approximately 125 employees. Adocia is a company listed on the Euronext marketTM Paris (Euronext: ADOC; ISIN: FR0011184241).

caveat

This press release contains forward-looking statements about Adocia and its business. Adocia believes that these forward-looking statements are based on reasonable assumptions. However, we cannot guarantee the achievement of the forecasts shown in these forward-looking statements. These forecasts are subject to risks, including those described in Adocia’s Universal Registration Document filed with the Autorité des marchés financial institution on April 21, 2022. Uncertainty inherent in Adocia’s website (www.adocia.com), especially R & D, future clinical data, analysis, and economic conditions, financial markets, and market changes in which Adocia resides. The forward-looking statements contained in this press release are also exposed to risks that Adocia does not know about or that Adocia does not consider materiality at this time. The realization of all or part of these risks may result in Adocia’s actual results, financial position, performance or performance significantly differing from the results expressed in these Declarations. there is. This press release and the information contained therein do not constitute an offer to sell or subscribe, or solicit an order to purchase or subscribe to Adocia shares in any country.

contact address

For more information

Adoshia
Gerald Surah
CEO

[email protected]
+33 4 72 610 610

www.adocia.com

Ulysses Communication
Relationship between Adocia Press and Investors

Pierre Louis Germain
[email protected] / + 33 (0) 6 64 79 97 51

Arisak’s Margopeek Country
[email protected] / +33 (0) 7 86 16 01 09

Bruno Arabian
[email protected] / +33 (0) 6 87 88 47 26